Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis - Takeaways - MDSpire

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

  • By

  • Kerri Miller

  • March 17, 2026

  • 4 min

Share

  • 1

    Lebrikizumab met co-primary and key secondary end points in pediatric patients with moderate-to-severe atopic dermatitis in the Phase 3 ADorable-1 trial.

  • 2

    In the trial, 63% of patients on lebrikizumab achieved a 75% reduction in EASI score, compared to 22% in the placebo group.

  • 3

    The trial showed that 44% of lebrikizumab patients had an IGA score of 0 or 1, indicating clear skin, versus 15% with placebo.

  • 4

    Lebrikizumab's safety profile was consistent with previous studies, with common adverse events being upper respiratory infections and nasopharyngitis.

  • 5

    The ongoing ADorable-2 study will follow patients for up to 52 weeks, as lebrikizumab aims for potential label expansion for younger patients.

Original Source(s)

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

  • by Kerri Miller

  • March 17, 2026

Related Content

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review

Facial Hemangiomas May Signal PHACE

Early recognition of segmental facial lesions prompted diagnosis and multidisciplinary care in an infant with multisystem involvement

Atopic Dermatitis Treatment Targets Defined

Consensus definitions for disease control in atopic dermatitis aim to standardize clinical trial end points and support treat-to-target strategies.